Singer et al. demonstrated that human lung adenocarcinoma cells expressing CEA have significantly reduced survival [55], while Spindler et al. showed that pre-treatment CEA plasma levels of patients with metastatic CRC treated with Cetuximab and Irinotecan were not associated with differences in overall survival or progression-free survival, while TIMP-1 showed significant prognostic value [64]. This evidence concerns the gene TIMP1 and lung adenocarcinoma.